#China #Qingdao #medical equipment #Euromonitor #Haier Biomedical

Haier Biomedical: A Leader in Global Lab Equipment

Haier Biomedical, listed under SHA: 688139, has been recognized as the number one Chinese brand in the global sales of medical laboratory equipment, and it achieved the same rank for overseas sales categories according to the 2025 data from Euromonitor International. The double recognition underscores Haier Biomedical’s position at the forefront of the global competitive landscape while simultaneously concluding a successful three-phase international expansion initiative.

A Major Milestone

The recognition from Euromonitor International, a prominent independent market research firm, serves as a comprehensive benchmark in global procurement and industry analysis. The rankings account for total revenue from global sales and sales figures from abroad among Chinese brands in the medical laboratory equipment sector. This validation allows Haier Biomedical to compete effectively with renowned international manufacturers in diverse global markets.

Furthermore, these rankings carry substantial weight for international partners. In an industry where equipment reliability, compliance, and long-term service support are critical factors in procurement decisions, the independent confirmation of market leadership offers an added layer of trust for institutions assessing suppliers.

Strategic International Growth

Haier Biomedical's international growth started through targeted projects, engaging directly with organizations like UNICEF and WHO to address specific challenges, particularly in creating reliable solar-powered vaccine storage solutions. Following these initial successes, the company expanded its distributor network to include 160 countries by establishing partnerships with over 800 dealers.

Currently, the emphasis is on operational capabilities in key regions, including local warehouses, sales, marketing, product planning, and R&D. The company is now operating international research centers in countries like the UK, Italy, and Japan. Each center focuses on specific production lines, which include centrifuges, refrigeration systems, storage automation solutions, incubators, and biosafety cabinets.

Haier Biomedical’s specialists in the UK and continental Europe work to ensure compliance with good manufacturing practice (GMP) requirements, air stability, and sample safety, positioning the company as an essential partner in laboratory workflows.

The service standards developed in the USA and UK are now employed in the EU, Southeast Asia, and Southern Asia, highlighting the global consistency of their operations.

Significant Revenue Growth

In the first quarter of 2026, revenues in Germany, Australia, and Canada surged by over 50%. Meanwhile, in Eastern Europe, South Asia, and Brazil, the annual growth exceeded 100%, with sales of centrifuges and incubators doubling in figures. Within the pharmaceutical sector, Haier Biomedical has become a pivotal player in supply chains for numerous leading pharmaceutical companies in key nations, such as Switzerland, Germany, and the USA, affirming its place in the global market.

The Ultra Energy series has dominated the US Energy Star rankings within its category, establishing itself as a best-selling lineup.

Future Steps and Strategies

Looking ahead, Haier Biomedical plans to amplify its investment in localization, expanding its product assortment in a bid to assist global biopharmaceutical and medical laboratory facilities in enhancing efficiency and sustainability. The company aims to lead in providing integrated tools for the life sciences and intelligent manufacturing platforms worldwide.

For more insights, please visit Haier Biomedical.